{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:26Z","timestamp":1753891886602,"version":"3.41.2"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nucl. Med."],"abstract":"<jats:p>Breast cancer commonly metastasises to the skeleton, and stereotactic ablative body radiation therapy (SABR) is an emerging treatment for oligometastatic disease. Accurately imaging bone metastases and their response to treatment is challenging. [<jats:sup>18<\/jats:sup>F]NaF-PET has a higher sensitivity and specificity than conventional bone scans for detecting breast cancer bone metastases. In this pre-defined secondary analysis of a prospective trial, we evaluated the change in [<jats:sup>18<\/jats:sup>F]NaF uptake after SABR. Patients with oligometastatic breast cancer received a single fraction of 20\u2005Gy to up to three bone metastases. [<jats:sup>18<\/jats:sup>F]NaF-PET was acquired before and 12 months after SABR. Pre- and post-treatment [<jats:sup>18<\/jats:sup>F]NaF-PET images were registered to the treatment planning CT. The relative change in tumour SUV<jats:sub>max<\/jats:sub> and SUV<jats:sub>mean<\/jats:sub> was quantified. The intersection of each of the radiation therapy isodose contours with a non-tumour bone was created. The change in SUV<jats:sub>mean<\/jats:sub> in sub-volumes of non-tumour bone receiving doses of 0\u201320\u2005Gy was quantified. In total, 14 patients, with 17 bone metastases, were available for analysis. A total of 15 metastases exhibited a reduction in SUV<jats:sub>max<\/jats:sub>; the median reduction was 42% and the maximum reduction 82%. An increased absolute reduction in SUV<jats:sub>max<\/jats:sub> was observed with higher pre-treatment SUV<jats:sub>max<\/jats:sub>. One patient exhibited increased SUV<jats:sub>max<\/jats:sub> after treatment, which was attributed to normal peri-tumoural bone regeneration in the context of a bone metastasis. There was a median reduction of 15%\u201334% for non-tumour bone in each dose level.<\/jats:p>","DOI":"10.3389\/fnume.2023.1197397","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T09:27:33Z","timestamp":1696411653000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["[18F]NaF PET\/CT imaging of response to single fraction SABR to bone metastases from breast cancer"],"prefix":"10.3389","volume":"3","author":[{"given":"Nicholas","family":"Hardcastle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"Br J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10549-015-3341-3","article-title":"Impact of breast cancer subtypes and patterns of metastasis on outcome","volume":"150","author":"Kast","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"B3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1023\/A:1006308619659","article-title":"Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis","volume":"59","author":"Solomayer","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"B4","doi-asserted-by":"publisher","first-page":"27S","DOI":"10.2967\/jnumed.115.157867","article-title":"Imaging bone metastases in breast cancer: staging and response assessment","volume":"57","author":"Cook","year":"2016","journal-title":"J Nucl Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.7150\/jca.1.80","article-title":"Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST","volume":"1","author":"Costelloe","year":"2010","journal-title":"J Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S1470-2045(09)70088-9","article-title":"Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis","volume":"10","author":"Costelloe","year":"2009","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1200\/JCO.2004.08.181","article-title":"Bone imaging in metastatic breast cancer","volume":"22","author":"Hamaoka","year":"2004","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00259-002-0880-8","article-title":"FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters","volume":"29","author":"Buck","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4329\/wjr.v7.i8.202","article-title":"Imaging of bone metastasis: an update","volume":"7","author":"O\u2019Sullivan","year":"2015","journal-title":"World J Radiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"115267","DOI":"10.1016\/j.bone.2020.115267","article-title":"Correlation between (18)F-sodium fluoride positron emission tomography and bone histomorphometry in dialysis patients","volume":"134","author":"Aaltonen","year":"2020","journal-title":"Bone"},{"key":"B11","doi-asserted-by":"publisher","first-page":"110081","DOI":"10.1016\/j.ejrad.2021.110081","article-title":"Correlation of the quantitative methods for the measurement of bone uptake and plasma clearance of (18)F-NaF using positron emission tomography. Systematic review and meta-analysis","volume":"146","author":"Assiri","year":"2022","journal-title":"Eur J Radiol"},{"key":"B12","first-page":"332","article-title":"Fluorine-18: a new isotope for bone scanning","volume":"3","author":"Blau","year":"1962","journal-title":"J Nucl Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1088\/0143-0815\/7\/4\/003","article-title":"The single-passage extraction of 18F in rabbit bone","volume":"7","author":"Wootton","year":"1986","journal-title":"Clin Phys Physiol Meas"},{"key":"B14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s11604-013-0179-7","article-title":"The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET\/CT and 99mTc-MDP bone scan","volume":"31","author":"Damle","year":"2013","journal-title":"Jpn J Radiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s13139-012-0178-0","article-title":"Usefulness of (18)F-fluoride PET\/CT in breast cancer patients with osteosclerotic bone metastases","volume":"47","author":"Yoon","year":"2013","journal-title":"Nucl Med Mol Imaging"},{"key":"B16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.breast.2019.10.016","article-title":"Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: a prospective clinical trial","volume":"49","author":"David","year":"2020","journal-title":"Breast"},{"key":"B17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.2967\/jnumed.118.211102","article-title":"Prospective study of serial (18)F-FDG PET and (18)F-fluoride PET to predict time to skeletal-related events, time to progression, and survival in patients with bone-dominant metastatic breast cancer","volume":"59","author":"Peterson","year":"2018","journal-title":"J Nucl Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00259-018-4223-9","article-title":"Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [(18)F] fluorodeoxyglucose and [(18)F]-fluoride PET\/CT with whole-body MRI with diffusion-weighted imaging","volume":"46","author":"Azad","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B20","doi-asserted-by":"publisher","first-page":"322","DOI":"10.2967\/jnumed.118.208710","article-title":"Is response assessment of breast cancer bone metastases better with measurement of (18)F-fluoride metabolic flux than with measurement of (18)F-fluoride PET\/CT SUV?","volume":"60","author":"Azad","year":"2019","journal-title":"J Nucl Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13014-019-1359-0","article-title":"Naf PET\/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy","volume":"14","author":"Hardcastle","year":"","journal-title":"Radiat Oncol"},{"year":"2019","key":"B22"},{"year":"2019","key":"B23"},{"key":"B24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40336-020-00363-3","article-title":"Comparison between 18F-FDG and 18F-NaF PET imaging for assessing bone metastases in breast cancer patients: a literature review","volume":"8","author":"Taralli","year":"2020","journal-title":"Clin Transl Imaging"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","article-title":"NRG-BR002: a phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557)","volume":"40","author":"Chmura","year":"2022","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ctro.2021.03.012","article-title":"Metastases-directed radiotherapy in addition to standard systemic therapy in patients with oligometastatic breast cancer: study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA)","volume":"28","author":"Krug","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"year":"","author":"Linderholm","key":"B28"},{"year":"","author":"Shao","key":"B29"},{"year":"","author":"Bonadio","key":"B30"},{"year":"","author":"Yerramilli","key":"B31"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.2967\/jnumed.116.177295","article-title":"Repeatability of quantitative 18F-NaF PET: a multicenter study","volume":"57","author":"Lin","year":"2016","journal-title":"J Nucl Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00259-011-1966-y","article-title":"Estimation of regional bone metabolism from whole-body 18F-fluoride PET static images","volume":"39","author":"Siddique","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Frontiers in Nuclear Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnume.2023.1197397\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T08:59:41Z","timestamp":1728291581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnume.2023.1197397\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":33,"alternative-id":["10.3389\/fnume.2023.1197397"],"URL":"https:\/\/doi.org\/10.3389\/fnume.2023.1197397","relation":{},"ISSN":["2673-8880"],"issn-type":[{"type":"electronic","value":"2673-8880"}],"subject":[],"published":{"date-parts":[[2023,10,4]]},"article-number":"1197397"}}